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There is an urgent need for the development of new antimalarial compounds. As a result of a phenotypic
screen, several compounds with potent activity against the parasite Plasmodium falciparum were iden-
tiﬁed. Characterization of these compounds is discussed, along with approaches to optimise the physi-
cochemical properties. The in vitro antimalarial activity of these compounds against P. falciparum K1 had
EC50 values in the range of 0.09e29 mM, and generally good selectivity (typically >100-fold) compared to
a mammalian cell line (L6). One example showed no signiﬁcant activity against a rodent model of ma-
laria, and more work is needed to optimise these compounds.
© 2015 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Malaria is a serious endemic disease and is a major threat to
public health in more than 100 countries [1,2]. It affects about 200
million people per year, with approximately 580,000 associated
deaths [3,4]. In addition malaria exerts a huge economic toll in
endemic countries [3]. The need for a continual supply of new
antimalarial therapeutics is still as relevant as ever.
Malaria is caused by protozoan parasites of the species Plas-
modium [5], with Plasmodium falciparum being responsible formost
malaria-related deaths. In many areas malaria parasites have
developed resistance to chemotherapeutic agents such as chloro-
quine, meﬂoquine, and sulfadoxine/pyrimethamine. Therefore, an
urgent need exists to develop new classes of antimalarial drugs that
operate by novel mechanisms of action.
We have recently reported the identiﬁcation of a hit (TDR32750)
[6,7] from a screen of the ChemDiv5000 ‘maximally structurally
diverse’ compound collection against P. falciparum. This screen was
carried out by the World Health Organisation Programme for
Research and Training in Tropical Medicine (Fig. 1). TDR32750acokinetics; SAR, structure-
on; WHO-TDR, World Health
Tropical Diseases.
ert).
r Masson SAS. This is an open acceshowed potent activity against P. falciparum (EC50 ¼ 9 nM), and
good selectivity compared to L6 mammalian cells (>2000-fold). In
order to follow up on the hit, other analogues from ChemDiv and
PrincetonBio were screened. This led to identiﬁcation of two more
hits, TDR45024 and TDR45033 (Fig. 1), which shared the N-aryl-
pyrrole found in TDR32750.
In this paper we report the follow up of these compounds,
TDR45024 and TDR45033; systematic structure-activity relation-
ship studies were undertaken with the aim of improving anti-
parasitic activity, and to generate compounds with drug-like
physicochemical and pharmacokinetic properties. The studies
encompassed variation of the phenyl ring attached to the pyrrole,
modiﬁcation of the pyrrole and modiﬁcation of the thiazolidine-
dione ring. The activity of compounds against the chloroquine and
pyrimethamine resistant (K1) strain of P. falciparum is reported, as
well as a counter-screen (EC50) against the L6 murine cell line, to
provide an indication of selectivity (Table 1, Fig. 2).2. Results and discussion
2.1. Synthesis of cyclohexyl-2-(phenylimino)-4-thiazolidinedione
analogues (20e32)
The thiazolidinedione core [8,9] (3) was prepared by conden-
sation of the commercially available 1-cyclohexyl-3-phenyl-2-
thiourea (1) with monochloroacetic acid (2; Scheme 1). This wasss article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. The hit TDR32750 and follow-up compounds.
Table 1
In vitro activity of phenyliminothiazolidinones against P. falciparum and L6 cells.






20 Me 2.0 >190 6.6 2.7
21 Me 0.42 >170 7.2 3.1
22 Me 0.25 >200 6.6 2.6
23 Me 0.25 >170 7.5 3.2
24 Me 1.9 >170 7.5 3.2
25 Me 0.78 >170 7.5 3.2
26 Me 0.09 >170 6.5 3.1
27 Me 0.61 71 5.4 1.9
28 H 2.3 >180 6.7 2.9
29 H 1.6 >200 6.1 2.2
30 Me 3.4 23 5.1 1.5
31 Me 1.9 >230 5.6 1.5
32 e e 1.9 >180 6.1 2.6
a Plasmodium falciparum.
b Measure of cytotoxicity; nd: not determined. Controls: for P. falciparum K1, chloroquine, EC50 ¼ 0.1 mg/ml; for cytotoxicity (L6 cells), podophyllotoxin, EC50 ¼ 0.005 mg/ml.
The EC50 values are the data are means of two independent assays run in singleton. Yields for compounds 20e32 are 40e80%.
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Fig. 2. Outline of derivatives prepared.
Scheme 1. General Synthetic Approach to thiazolidin-4-ones: (a) sodium acetate, ethanol, 0 C, 30 min, 20%; (b) p-toluenesulfonic acid bound with silica gel, microwave (0e400 W
at 2.45 GHz), 180 C, 15e20 min, 80e90%; or p-toluenesulfonic acid, toluene, 90 C, 3 h, DeaneStark Apparatus; (c) phosphorous oxychloride, DMF, 100 C, 3 h, 80e95%; (d)
piperidine, ethanol, 3 h, reﬂux, 20%.
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ucts (20e32). We have previously reported the preparation of a
number of the 3-formylpyrroles (7) used here [7]. They were ob-
tained by condensation of the appropriate aniline with 2,5-hex-
anedione (4) (PaaleKnorr pyrrole synthesis), and subsequent
VilsmeiereHaack formylation.
3-Formyl pyrroles without the 2,5-dimethyl substitution were
prepared (Scheme 2). We have previously reported the preparation
of compound 7j through condensation of o-triﬂuoromethyl aniline
with 2,5-dimethoxy tetrahydrofuran-3-carboxaldehyde (8) [7].
Compound 7m was similarly prepared using benzylamine. The
pyrroles 7j [10,11] and 7m were then condensed with the thiazo-
lidinedione core to give the desired products 28 and 29. Similarly
the pyrrole could be replaced by a pyrazole [12]. As we have pre-
viously reported, the 3-formylpyrazole 7n was prepared by
condensation of 1,1,3,3-tetramethoxypropane 9 and 2-(tri-
ﬂuoromethyl)phenyl hydrazine 10, followed by VilsmeiereHaack
formylation [7]. This was condensed with the thiazolidinedione
core 3 to give the desired product 32 in a yield of 65%.2.2. Modiﬁcation of the thiazolidinedione core
The lipophilic cyclohexyl and N-phenyl groups from thethiazolidinedione core were replaced with methyls (Scheme 3), in
order to improve the physicochemical properties of the molecule.
We also investigated replacing the N-imino group on the thia-
zolidinedione with an oxygen and replacing the thiazolidinedione
ring altogether with a barbituric acid moiety (Scheme 4).2.3. Stereochemistry
There are two potential stereocenters; in compounds 20e42,
the exocyclic double bond to the imine; the exocyclic double bond
to the pyrrole. Literature precedent [13], suggests the stereo-
chemistry of these double bonds is (Z,Z). In the case of the exocyclic
double bond to the imine, an E-conﬁguration is highly unlikely as
there would be steric clashes between the substituent on the imine
(in the case of compound 20, the phenyl), with the substituent on
the ring nitrogen (in the case of compound 20, the cyclohexyl). In
the case of the exocyclic double bond to the pyrrole, the 1H NMR
signal of the exocyclic alkenic proton is indicative of the Z-stereo-
isomer. As in the literature precedent [13], this proton (HC]C) is
de-shielded by the carbonyl group and for most of the compounds
(20e43) appeared with chemical shifts in the range of
7.65e8.35 ppm.
Scheme 2. (a) 2-Triﬂuoromethyl aniline (7j) or benzyl amine (7m), glacial acetic acid, 90 C, 80%; (b) thiazolidinedione (3), piperidine, ethanol, 3 h, reﬂux, 80e95%; (c) ethanol, H2O,
HCl, 90 C, 3 h; (d) phosphorous oxychloride, DMF, 100 C, 3 h, 80e95% yield.
Scheme 3. (a) Anhydrous sodium acetate, ethanol; (b) 3-formyl pyrrole (7ce7n), piperdine, ethanol, 3 Å molecular sieves, 90 C, 10 h.
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The compounds (20e32) were assayed against P. falciparum K1
strain [14], and counter-screened in mammalian L6-cells [15].3.1. Modiﬁcations of the cyclohexyl-2-(phenylimino)-4-
thiazolidinedione derivatives (20e32, Table 1)
The synthesized compounds were found to show a fairly ﬂat
range of activities against P. falciparum K1 (EC50's 0.09e3.4 mM),
with the R1 group having relatively little affect on activity.
 The original hit molecules 20 and 21 were re-synthesised, and
identity and purity conﬁrmed; they had EC50 of 2.0 mM and
0.42 mM respectively.
 The other variants around the phenyl ring showed similar ac-
tivities: the unsubstituted phenyl (22, EC50 ¼ 0.25 mM); the
triﬂuoromethyl substituents (23, EC50 ¼ 0.25 mM, 24,
EC50 ¼ 1.9 mM, 25, EC50 ¼ 0.78 mM). The only exception to this is
the morpholine substituted derivative which showed a slight
improvement in potency (26, EC50 ¼ 0.09 mM). Replacement of the phenyl ring with a morpholine (27,
EC50¼ 0.61 mM), a hydrogen (30, EC50¼ 3.4 mM) or a methyl (31,
EC50 ¼ 1.9 mM) did not signiﬁcantly affect activity.
 Changes to the pyrrole ring also had little effect on potency:
including removal of the methyl groups (28, EC50 ¼ 2.3 mM); or
changing the pyrrole to a pyrazole (32, EC50 ¼ 1.9 mM).3.2. Modiﬁcations to the cyclohexyl-2-(phenylimino)-4-
thiazolidinedione core (33e52; Table 2)
 Replacing the cyclohexyl ring on the thiazolidinedione with
methyl (33e38) gave a drop in potency of between 2 and 10-fold
(EC50 ¼ 0.99e4.6 mM). However, given the drop in molecular
weight and logP, this is a relatively small loss in activity, but
gives an improvement in physicochemical properties.
 Replacement of the N-phenyl imine with an N-methyl imine
(39e43) also led to a small drop in activity (EC50 ¼ 3.6->13 mM),
compared to the parent analogues.
 Replacement of the imine with an oxygen 44e46, 49, 50with or
without a methyl group on the thiazolidinedione nitrogen (45)
gave a similar level in activity (EC50 ¼ 1.9e13 mM).
Scheme 4. (a) Piperdine, ethanol, 3 Å molecular sieves, 90 C, 8 h; (b) conc HCl, r.t, 1 h, 70e95%.
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analogues had low activity.
 The barbituric acid analogues were relatively inactive (51, 52)
(EC50 ¼ 16 and 29 mM, respectively).
 In addition, some of these compounds showed reduced selec-
tivity based in the L-6 assay.
4. Pharmacology
4.1. In vivo efﬁcacy studies in Plasmodium berghei mouse model
To establish proof of concept, compound 20 was taken forward
to the P. bergheimousemodel [16]. Compound 20 as a suspension in
aqueous DMSO was dosed intraperitoneally at 50 mg/kg for 4 days
but resulted in no signiﬁcant reduction in parasitaemia or increase
in survival time (Table 3).
5. Physiochemical properties and in vitro DMPK
The physicochemical properties of 20 were evaluated using a
combination of in silico and experimental techniques, and the
metabolic stability was assessed in vitro using human and mouse
liver microsomes, (Table 4). Compound 20 meets the Lipinski
criteria, except for the high lipophilicity with a logD of 7.1, which
explains the poor aqueous solubility at pH 2 and 6.5.
Compound 20 underwent rapid NADPH-dependent degradation
upon incubation with human and mouse liver microsomes,
(Table 5). There was no species difference in the relative rate of
metabolism between human and mouse liver microsomes, and no
obvious metabolites were detected using the analytical conditionsemployed for the parent compound. The rapid microsomal clear-
ance and low solubility probably explains the lack of activity of
compound 20 in the mouse model.
6. Conclusion
As a result of a phenotypic screen, some antimalarial com-
pounds were identiﬁed. Despite activity against P. falciparum
in vitro, an example compound was not active in a rodent model of
disease, most likely due to a combination of high metabolic turn-
over and low aqueous solubility arising from their relatively high
lipophilicity. To address these issues a number of analogues were
prepared with lower lipophilicity, measured by cLogP, but unfor-
tunately these showed no signiﬁcant improvement in potency
against the parasite. In order to progress this series further, com-
pounds need to be identiﬁed with improved potency and reduced
lipophilicity. A further impetus would come from an identiﬁcation
of the molecular target(s) of these compounds.
7. Materials and methods
7.1. General experimental information
Chemicals and solvents were purchased from Aldrich Chemical
Co. or Fluka, andwere used as received unless otherwise stated. Air-
and moisture-sensitive reactions were carried out under an inert
atmosphere of argon in oven-dried glassware. Analytical thin-layer
chromatography (TLC) was performed on pre-coated TLC plates
(layer 0.20 mm silica gel 60 with ﬂuorescent indicator UV254, from
Merck). Developed plates were air-dried and analysed under a UV
Table 2
In vitro activity against antiplasmodial and cytotoxic activity.






33 2.6 >230 4.5 1.8
34 2.2 >200 5.7 2.6
35 1.5 120 4.5 2.4
36 0.99 >210 3.3 1.1
37 3.9 >240 4.0 1.3
38 4.6 180 4.3 1.9
39 >13 >220 3.2 1.2
40 5.6 78 2.0 0.14
41 4.7 4 3.7 1.1
42 9.5 >290 2.8 0.10
(continued on next page)
Table 2 (continued )






43 3.6 34 3.1 0.7
44 1.9 64 4.0 4.0
45 2.2 >290 3.4 3.4
46 8.4 43 4.0 4.0
47 5.8 56 4.0 1.8
48 21 9 4.2 4.2
49 13 84 3.4 3.4
50 11 >320 2.3 2.3
51 16 120 2.9 2.9
52 29 16 3.3 3.3
a Plasmodium falciparum.
b Measure of cytotoxicity; nd: not determined. Controls: for P. falciparum, chloroquine K1, EC50 ¼ 0.1 mg/ml; for cytotoxicity (L6 cells), podophyllotoxin, EC50 ¼ 0.005 mg/ml.
The EC50 values are the data are means of two independent assays run in singleton. Yields for compounds 33e52, 40e80%.
c Conﬁguration as (Z,Z) 33e44, as (Z) 45,49e50, as (E) 46e48.
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formed using pre-packed silica gel cartridges (230e400 mesh,
40e63 mm, from SiliCycle) using a Teledyne ISCO Combiﬂash
Companion or Combiﬂash Retrieve. Microwave irradiation was
conducted using a BIOTAGE® INITIATOR unit. The machine consists
of a continuous focused microwave power delivery system with
operator-selectable power output (0e400 W at 2.45 GHz).1H NMR
and 13C NMR spectra were recorded on a Bruker Avance II 500
spectrometer (1H at 500.1 MHz, 13C at 125.8 MHz) or a Bruker
DPX300 spectrometer (1H at 300.1 MHz). Chemical shifts (d) areexpressed in ppm recorded using the residual solvent as the in-
ternal reference in all cases. Signal splitting patterns are described
as singlet (s), doublet (d), triplet (t), quartet (q), pentet (p), multi-
plet (m), broad (br), or a combination thereof. Coupling constants
(J) are quoted to the nearest 0.1 Hz. LC-MS analyses were performed
with either an Agilent HPLC 1100 series connected to a Bruker
DaltonicsMicroTOF or an Agilent Technologies 1200 series HPLC
connected to an Agilent Technologies 6130 quadrupole spectrom-
eter, where both instruments were connected to an Agilent diode
array detector. LC-MS chromatographic separations were
Table 3
In vivo antimalarial Activity against P. berghei (ANKA).
Dose (mg/kg/day  4) Route % Reduction parasitaemia P. berghei ANKA GFP Survival (days)
20 50 ipa 12 6
Chloroquine 10 ip 99.97 20
Control 7
a ip: intraperitoneal route of administration.
Table 4
Physicochemical data of 20.
Compound MW H-bond PSA FRB LogDa pH 7.4 Solubility (mg/ml)
Don Acc pH 2.0 pH 6.5
20 473.6 0 4 63 4 7.1 <0.8 0.8e1.6
a Value measured using the chromatographic gLogD technique.
Table 5
Metabolic stability of compound 20 based on NADPH-dependent degradation proﬁles in human/mouse liver microsomes.










20 Human 0.36 42 0.67 None
Mouse 0.055 216 0.71 None
a Intrinsic clearance.
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3.5 mm particle size; mobile phase, water/acetonitrile þ0.1%
HCOOH, or water/acetonitrile þ 0.1% NH3; linear gradient from
80:20 to 5:95 over 3.5 min and then held for 1.5 min; ﬂow rate of
0.5 mL min1. All assay compounds had a measured purity of 95%
(by total ion current (TIC) and UV) as determined using this
analytical LCMS system. High resolution electrospray measure-
ments were performed on a Bruker DaltonicsMicrOTOF mass
spectrometer.
7.2. (Z)-3-Cyclohexyl-2-(phenylimino)thiazolidin-4-one (3)A mixture of 3-cyclohexyl-1-phenyl-2-thiourea (5 g, 21 mmol),
monochloroacetic acid (2.02 g, 21 mmol), and anhydrous sodium
acetate (1.75 g, 21mmol) in absolute ethanol (100mL) was reﬂuxed
for 8e10 h. The reaction mixture was ﬁltered and the solvent was
evaporated under reduced pressure. The residue was puriﬁed by
column chromatography on a silica gel column (dichloromethane/
hexane) to give (1.44 g, 25%) of 3 as a yellowish solid, mp. 88-90 C.
1H NMR (500 MHz; CDCl3/Me4Si): d 7.28 (m, 2H), 7.06 (m, 1H), 6.86
(m, 2H), 4.39 (m, 1H), 3.65 (s, 2H), 2.34 (m, 2H), 1.79 (d, 2H,
J ¼ 13.45 Hz), 1.64 (d, 2H, J ¼ 4.9 Hz), 1.59 (d, 1H, J ¼ 12.75 Hz), 1.30
(m, 2H), 1.17 (m,1H); 13C NMR (125 MHz, CDCl3/Me4Si): d 172.1,
154.6, 148.5, 129.3 (2C), 124.5, 120.9 (2C), 56.1, 32.5 (2C), 28.1 (2C),
26.1, 25.1; HRMS (m/z): [MHþ] calcd for C15H18FN2OS, 275.0154;
found 275.2415.7.3. General procedure for the microwave-accelerated synthesis of
2,5-dimethyl-1-aryl-1H-pyrroles (6aei): [7]
2,5-Hexandione (4) (1 mmol), the appropriate aniline (5a-i)
(1.2 equiv) and p-toluenesulfonic acid bound with silica gel
(0.4 equiv) were mixed in oven dried pressure vials with magnetic
stir bars. The vessel was placed in a microwave oven and heated
(180 C, 15e20 min) under microwave irradiation (0e400 W at
2.45 GHz), then stirred for 15 min at room temperature. The silica
residue was removed by ﬁltration, washing with DCM (10 mL) The
solvent was removed under reduced pressure to give the 2,5-
dimethyl-1-aryl-1H-pyrroles (6a-i) (Purity >95% by HPLC, 80e90%
yield), which were used without further puriﬁcation.7.4. General procedure for the synthesis of 2,5-dimethyl-1-aryl-3-
formylpyrroles (7aei): [7]
As we have previously described [7] phosphorous oxychloride
(6 mmol) was added dropwise to stirred ice-cooled DMF (12 mL)
under a N2 atmosphere. The mixture was kept at room temperature
for 15 min and then a solution of the appropriate 2,5-dimethyl-1-
aryl-1H-pyrrole (6aei) (1 mmol) in DMF (5 mL) was added and
the mixture then heated at 100 C for 3 h under a N2 atmosphere.
After cooling 30% NaOH was added dropwise to adjust to pH ~10.
The solid precipitate was ﬁltered, washed with water and dried in
vacuo to afford the 2,5-dimethyl-1-aryl-3-formylpyrrole (7aei)
(80e95% yield), which was used without further puriﬁcation.7.5. General condensation procedure for cyclohexyl-2-
(phenylimino)thiazolidin-4-one; 3-methyl-2-(phenylimino)
thiazolidine-4-one; 3-methyl-2-(methylimino)thiazolidine-4-one;
thiazolidine-2,4-dione; 3-methyl thiazolidine-2,4-dione and
imidazolidine-2,4-dione derivatives (20e54)
To a solution of cyclohexyl-2-(phenylimino)-4-thiazolidineione,
3-methyl-2-(phenylimino) thiazolidine-4-one, thiazolidine-2,4-
dione, 3-methyl thiazolidine-2,4-dione or imidazolidine-2,4-
A. Mital et al. / European Journal of Medicinal Chemistry 103 (2015) 530e538538dione (1.0 equiv) in absolute ethanol (15 mL) was added the
appropriate 2,5-dimethyl-1-aryl -3-formylpyrrole (1.1 equiv),
piperidine (1.2 equiv) and 3 Ǻ molecular sieves. The mixture was
heated to reﬂux at 90 C for 8e10 h, cooled, ﬁltered and concen-
trated in vacuo. The residue was puriﬁed by column chromatog-
raphy on a silica gel column (ethylacetate/hexane or
dichloromethane/hexane) and in some cases recrystallized from
methanol to give 20e54 as generally yellowish solids.
7.5.1. (2Z, 5Z)-3-Cyclohexyl-5-((1-(4-ﬂuorophenyl)-2,5-dimethyl-
1H-pyrrol-3-yl)methylene)-2-(phenylimino)thiazolidin-4-one (20)
Yellowish solid, (0.100 g, 13%), mp. 225e227 C. 1H NMR
(500 MHz, CDCl3/Me4Si): d 7.69 (s, 1H, CH]C), 7.42 (t, 2H, J ¼ 7.88),
7.19 (m, 5H), 7.06 (m, 2H), 6.11 (s, 1H), 4.63 (m, 1H), 2.54 (m, 2H),
2.14 (s, 3H), 1.98 (s, 3H), 1.90 (d, 2H, J ¼ 18.10), 1.81 (d, 2H,
J¼ 11.45 Hz), 1.71 (d, 1H, J¼ 18.10 Hz), 1.44 (m, 2H), 1.31 (m,1H). 13C
NMR (125 MHz, CDCl3/Me4Si): d 167.7 (C]O), 163.3, 161.4, 151.5
(C]N), 149.1(C]C), 134.5, 133.7, 131.2, 129.8, 129.7, 129.3 (2C),
124.3, 124.2, 121.4, 116.6, 116.4, 115.8, 114.5, 105.5, 55.6, 28.5 (2C),
26.2, 25.3 (2C), 12.7, 11.0. Anal. Calc for C28H28FN3OS (473.60): C,
71.01; H, 5.96; N, 8.87; found: C, 68.91; H, 5.64; N, 8.38. HRMS (m/
z): [MHþ] calcd for C28H29FN3OS, 474.2015; found 474.2004.
7.5.2. (2Z,5Z)-3-Cyclohexyl-5-((1-(4-bromophenyl)-2,5-dimethyl-
1H-pyrrol-3-yl)methylene)-2-(phenylimino)thiazolidin-4-one (21)
Yellowish solid, (0.470 g, 24%), mp. 243e244 C. 1H NMR
(500 MHz, CDCl3/Me4Si): d 7.59 (s, 1H, CH]C), 7.55 (m, 2H), 7.32 (t,
2H, J ¼ 7.88 Hz), 7.10 (t, 1H, J ¼ 7.43 Hz), 6.97 (m, 4H), 6.02 (s, 1H),
4.53 (tt, 1H, J¼ 3.87, 4.89 Hz), 2.45 (m, 2H), 2.05 (s, 3H), 1.89 (s, 3H),
1.81 (m, 2H),1.72 (m, 2H),1.61 (m,1H),1.35 (m, 2H),1.20 (m,1H);13C
NMR (125 MHz, CDCl3/Me4Si): d 167.7 (C]O), 151.6 (C]N), 149.8
(C]C), 137.7, 136.8, 134.5, 134.2, 132.7, 131.3, 131.0, 129.6, 129.3,
124.3, 124.1, 122.7, 121.4, 116.0, 114.7, 112.2, 105.7, 55.6, 28.5 (2C),
26.2, 25.3 (2C), 12.7, 11.1; Anal. Calcd for C28H28BrN3OS (534.51): C,
62.92; H, 5.28; N, 7.86; found: C, 62.74; H, 5.19; N, 7.65. HRMS (m/z):
[MHþ] calcd for C28H29BrN3OS, 534.1215; found 534.1223.Acknowledgements
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